404 related articles for article (PubMed ID: 27932311)
1. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
3. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate system.
Zhang Y; Zou J; Zhao X; Yuan Z; Yi Z
J Gen Virol; 2019 Jan; 100(1):69-83. PubMed ID: 30516462
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
6. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
8. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein.
Lee C; Ma H; Hang JQ; Leveque V; Sklan EH; Elazar M; Klumpp K; Glenn JS
Virology; 2011 May; 414(1):10-8. PubMed ID: 21513964
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
[TBL] [Abstract][Full Text] [Related]
11. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
12. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
Liu D; Ji J; Ndongwe TP; Michailidis E; Rice CM; Ralston R; Sarafianos SG
Antimicrob Agents Chemother; 2015; 59(6):3482-92. PubMed ID: 25845863
[TBL] [Abstract][Full Text] [Related]
13. Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
Beldar S; Manimekalai MSS; Cho NJ; Baek K; Grüber G; Yoon HS
J Gen Virol; 2018 Feb; 99(2):194-208. PubMed ID: 29300159
[TBL] [Abstract][Full Text] [Related]
14. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
15. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
[TBL] [Abstract][Full Text] [Related]
16. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
[TBL] [Abstract][Full Text] [Related]
18. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Targett-Adams P; Graham EJ; Middleton J; Palmer A; Shaw SM; Lavender H; Brain P; Tran TD; Jones LH; Wakenhut F; Stammen B; Pryde D; Pickford C; Westby M
J Virol; 2011 Jul; 85(13):6353-68. PubMed ID: 21507963
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.
McGivern DR; Masaki T; Williford S; Ingravallo P; Feng Z; Lahser F; Asante-Appiah E; Neddermann P; De Francesco R; Howe AY; Lemon SM
Gastroenterology; 2014 Aug; 147(2):453-62.e7. PubMed ID: 24768676
[TBL] [Abstract][Full Text] [Related]
20. Human Choline Kinase-α Promotes Hepatitis C Virus RNA Replication through Modulation of Membranous Viral Replication Complex Formation.
Wong MT; Chen SS
J Virol; 2016 Oct; 90(20):9075-95. PubMed ID: 27489281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
